Zentalis to present positive Phase 1b data for azenosertib in ovarian cancer at ASCO; announces diagnostic partnerships

Zentalis Pharmaceuticals, Inc.

Positive clinical data from Phase 1b trial of azenosertib + chemo in platinum-resistant ovarian cancer to be presented at ASCO June 5, 2023.
Cyclin E1 expression shown as predictive marker for clinical benefit from azenosertib.
Collaborations with Foundation Medicine and Roche Diagnostics to develop companion diagnostics for azenosertib.
Azenosertib is potentially first-in-class Wee1 inhibitor being investigated in multiple trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.